Weight Loss Peptide Dosage Protocols
GLP-1 receptor agonists, dual and triple incretin agonists, and metabolic accelerators dominate the modern obesity research landscape. This directory covers Retatrutide, Tirzepatide, Semaglutide, Cagrilintide, Survodutide, Mazdutide, and related compounds with full titration schedules and clinical trial citations.
11 protocols indexed
Survodutide
Survodutide (BI 456906) is a once-weekly dual glucagon-receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist developed jointly by Boehringer Ingelheim and Zealand Pharma. In the Phase 2 dose-finding trial of 386 adults with overweight or obesity without diabetes, survodutide 4.8 mg weekly produced a mean body-weight reduction of 14.9% (all data) and 18.7% (on-treatment data) at 46 weeks versus 2.8% with placebo, with nearly 40% of high-dose participants losing ≥20% [1]. The drug is investigational — not FDA, EMA or any other regulator approved — and remains in Phase 3 development across the SYNCHRONIZE program for obesity, type 2 diabetes and MASH; topline obesity data are expected to read out in 2026–2027. Standard Phase 3 dosing escalates weekly from 0.6 mg through 1.2, 1.8, 2.4, 3.6, 4.8 and 6.0 mg over a 10–12 week titration.
Open Protocolarrow_forwardIncretin Mimetic & GLP-1Tirzepatide
Tirzepatide is a once-weekly synthetic 39-amino-acid peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, manufactured by Eli Lilly and marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. In the Phase 3 SURMOUNT-1 trial of 2,539 adults without diabetes, tirzepatide 15 mg weekly produced a mean body-weight reduction of 20.9% at 72 weeks versus 3.1% with placebo, with 57% of participants losing at least 20% of body weight [1]. FDA approval for type 2 diabetes was granted in May 2022 and for chronic weight management in November 2023; tirzepatide is approved in the EU, UK, Japan, China and most major markets. Doses escalate monthly from 2.5 mg up to 5, 7.5, 10, 12.5 and a 15 mg maintenance ceiling.
Open Protocolarrow_forwardResearch Peptide5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule (not peptide) inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that catalyzes the methylation of nicotinamide using S-adenosyl-methionine as a methyl donor — a reaction that depletes both the methyl pool and the precursor pool for NAD+ synthesis. Developed from structure-activity work at the University of Texas at Austin, 5-Amino-1MQ was first reported by Neelakantan and colleagues (Biochem Pharmacol 2018) to reverse high-fat-diet-induced obesity in mice without affecting food intake [1]. A second paper from the same group (Neelakantan et al., 2019) showed activation of senescent muscle stem cells and improvement in skeletal-muscle regeneration in aged mice [2]. 5-Amino-1MQ is investigational only, has no FDA approval for any indication, and is sold by research-chemical suppliers as a laboratory compound. Typical research dosing is 50–150 mg daily orally for 4–12 week cycles.
Open Protocolarrow_forwardResearch PeptideAdipotide
Adipotide (FTPP, fat-targeting peptide-peptidomimetic) is a 22-amino-acid bipartite peptide consisting of a homing sequence (CKGGRAKDC) that selectively binds prohibitin on white-adipose-tissue blood vessels, conjugated via a glycine-glycine linker to a pro-apoptotic peptidomimetic sequence D(KLAKLAK)2 that disrupts mitochondrial membranes when internalized. Discovered by Kolonin and colleagues using in vivo phage display in obese mice and reported in Nature Medicine 2004 [1], the molecule was subsequently shown to produce 11% body-weight reduction in obese rhesus monkeys over 4 weeks (Barnhart et al., Science Translational Medicine 2011) [2]. Adipotide is investigational only — never tested in randomized human obesity trials, with the only registered human work being a small Phase 1 oncology trial in metastatic prostate cancer that was completed in 2014. The drug is not FDA approved, not in active clinical development for obesity, and remains a research-chemical compound.
Open Protocolarrow_forwardIncretin Mimetic & GLP-1Cagrilintide
Cagrilintide is a long-acting synthetic analogue of human amylin, the pancreatic hormone co-secreted with insulin that regulates satiety, gastric emptying and glucagon suppression. Developed by Novo Nordisk for once-weekly subcutaneous administration, it was designed as a partner peptide for semaglutide in the fixed-dose combination CagriSema. In the Phase 2 dose-finding trial published in The Lancet, cagrilintide 4.5 mg weekly produced a mean body-weight reduction of 10.8% at 26 weeks vs 3.0% with placebo, with cagrilintide 4.5 mg also out-performing daily liraglutide 3.0 mg on weight loss [1]. Cagrilintide as monotherapy is investigational and not FDA approved; the CagriSema combination was submitted for FDA NDA review in December 2025 based on REDEFINE Phase 3 data. Cagrilintide dosing escalates weekly from 0.16 mg through 0.3, 0.6, 1.2, 2.4 and 4.5 mg over 16–20 weeks.
Open Protocolarrow_forwardResearch PeptideAOD-9604
AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic domain of human growth hormone (residues 177–191) with a tyrosine modification at position 177. Originally developed by Metabolic Pharmaceuticals (Australia) and characterized by Heffernan and colleagues, it was designed to retain the fat-mobilizing activity of full-length growth hormone while avoiding its anabolic and diabetogenic effects [1]. Six Phase 1 and Phase 2 human trials enrolling roughly 900 participants demonstrated a clean safety profile, but efficacy was modest: a 12-week placebo-controlled trial in obese adults showed mean weight loss of 2.6 kg on 1 mg/day AOD-9604 vs 0.8 kg on placebo, leading the manufacturer to halt obesity development in 2007 [2]. AOD-9604 is not FDA approved as a drug, holds GRAS (Generally Recognized as Safe) status from the FDA as a food/cosmetic ingredient, and is sold by research-chemical suppliers strictly for laboratory use. Typical research dosing is 250–500 mcg daily subcutaneously.
Open Protocolarrow_forwardIncretin Mimetic & GLP-1Mazdutide
Mazdutide (IBI362, LY3305677) is a once-weekly dual glucagon-receptor and GLP-1 receptor agonist engineered as an analogue of the endogenous gut hormone oxyntomodulin. It was originally discovered by Eli Lilly, then out-licensed to Innovent Biologics for development across Greater China and other Asian markets. In the Phase 3 GLORY-1 trial of Chinese adults with overweight or obesity, mazdutide 6 mg weekly produced a mean body-weight reduction of 14.0% at 48 weeks, with 49.5% of participants losing at least 15% of body weight versus 2.0% on placebo [1]. Mazdutide is investigational in the United States and most of Europe but received its first NDA acceptance from China's NMPA in February 2024 for chronic weight management — approval is anticipated in 2025–2026. Standard dosing escalates from 1.5 mg weekly to 3, 4.5, 6 and up to 9 mg over 12–16 weeks.
Open Protocolarrow_forwardIncretin Mimetic & GLP-1Retatrutide
Retatrutide (LY3437943) is a once-weekly triple-receptor agonist that activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors in a single peptide backbone, combining appetite suppression with thermogenic energy expenditure. In the Phase 2 TRIUMPH-2 trial published in NEJM, adults with obesity receiving 12 mg weekly achieved a placebo-adjusted mean weight reduction of 24.2% at 48 weeks, the largest pharmacologic weight loss reported to date and with no apparent plateau on the dose-response curve [1]. The 9 mg and 12 mg arms of the Phase 3 TRIUMPH-4 trial confirmed up to 28.7% weight reduction in adults with obesity and knee osteoarthritis at 68 weeks [2]. Retatrutide is investigational, not FDA approved, and remains restricted to clinical-trial use; it is sold by chemical suppliers as a research compound only.
Open Protocolarrow_forwardIncretin Mimetic & GLP-1Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist developed by Novo Nordisk and marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral T2D). In the pivotal Phase 3 STEP-1 trial of 1,961 adults with overweight or obesity without diabetes, weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo, with 86% of treated participants achieving at least 5% loss [1]. Semaglutide is FDA approved for T2D (Ozempic, 2017), chronic weight management (Wegovy, 2021) and cardiovascular risk reduction in adults with obesity and established CVD (Wegovy expansion, 2024 — based on SELECT). Standard dosing is a 16-week titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, increasing every 4 weeks.
Open Protocolarrow_forwardTherapeutic BlendAOD-9604 + CJC-1295 + Ipamorelin
The AOD-9604 + CJC-1295 + Ipamorelin stack is a research-protocol blend combining a synthetic hGH lipolytic fragment (AOD-9604) with two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin-receptor agonist). The combination rationale is mechanistic complementarity — AOD-9604 stimulates beta-3 adrenergic lipolysis directly in adipocytes [1] while CJC-1295 + ipamorelin amplifies endogenous pulsatile growth-hormone secretion through the GHRH and ghrelin axes respectively, producing a sustained GH/IGF-1 elevation believed to enhance fat mobilization and lean-tissue preservation [2][3]. No randomized clinical trial has tested this combination; the stack is used exclusively in research-chemical and compounded-prescription contexts. None of the three components is FDA approved as a drug. Typical research dosing: AOD-9604 250–500 mcg/day SC, CJC-1295 (no-DAC) 100–200 mcg pre-bed SC, Ipamorelin 100–200 mcg pre-bed SC.
Open Protocolarrow_forwardTherapeutic BlendCagrilintide + Semaglutide
CagriSema is the fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), both at 2.4 mg weekly, developed by Novo Nordisk and submitted to the FDA in December 2025 based on the Phase 3 REDEFINE-1 trial. The combination exploits complementary satiety pathways: cagrilintide engages amylin/calcitonin-receptor signaling in the brainstem while semaglutide acts on hypothalamic GLP-1 receptors — producing an additive rather than redundant effect on appetite suppression and weight loss. In REDEFINE-1, CagriSema 2.4/2.4 mg weekly produced 22.7% mean weight loss at 68 weeks compared to 11.8% with cagrilintide alone, 16.1% with semaglutide alone, and 2.3% with placebo [1]. CagriSema is not yet FDA approved (NDA review expected to complete in 2026). Standard dosing escalates both peptides in parallel through a 16–20 week titration to the 2.4 mg / 2.4 mg maintenance dose.
Open Protocolarrow_forward